Munich, Germany, and London, UK, 6 February 2007 - Trigen, the cardiovascular drug discovery and development company, today announced that following completion of appropriate regulatory procedures at the United States Federal Drug Administration (FDA), the Investigational New Drug (IND) application for flovagatran (formerly TGN 255) is open. Flovagatran is the company’s novel intravenous direct thrombin inhibitor (DTI). Trigen intends to initiate the registration programme for flovagatran in the USA and other countries by studying the drug’s ability to prevent thrombosis (clotting) in the extracorporeal circuit of haemodialysis patients.
